Orforglipron: FDA-Approved Weight Loss Pill Guide 2026

Orforglipron is the first once-daily oral GLP-1 receptor agonist pill approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Sold under the brand name Foundayo by Eli Lilly, it works without injections, without refrigeration, and without any food or water restrictions. For patients who have avoided GLP-1 medications because of needles or complicated instructions, orforglipron changes what daily treatment looks like. This guide walks through pricing, dosage, side effects, how it compares to tirzepatide and semaglutide, and where it fits into a real weight loss plan.

What Is Orforglipron?

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist taken as a once-daily tablet. Unlike injectable GLP-1 drugs, which are peptide-based and need to be stored cold, orforglipron is a stable pill you can carry in your bag. It was originally discovered by Chugai Pharmaceutical in Japan and licensed to Eli Lilly in 2018. The medication is FDA-approved for adults with a BMI of 30 or higher or a BMI of 27 with a weight-related medical problem such as type 2 diabetes, high blood pressure, or high cholesterol.

Foundayo (Orforglipron) Brand Name and FDA Approval

The FDA approved orforglipron on April 1, 2026, under the brand name Foundayo. This was the fifth approval under the FDA’s Commissioner’s National Priority Voucher pilot program and the fastest new molecular entity approval since 2002. Approval was based on the phase 3 ATTAIN clinical development program, which studied more than 3,000 adults over 72 weeks. Foundayo joined the market shortly after Novo Nordisk’s oral semaglutide (Wegovy pill) received its own FDA nod for weight loss in December 2025.

Orforglipron Mechanism of Action: How Does It Work?

Orforglipron mimics GLP-1, a natural hormone your gut releases after eating. By binding to GLP-1 receptors, it slows how quickly your stomach empties, signals your brain that you’re full sooner, and helps regulate blood sugar. The result is reduced appetite, smaller portions, and steadier glucose control. Because it’s a small molecule rather than a peptide, it survives digestion and reaches the bloodstream through a pill instead of an injection.

Orforglipron Price, Cost Per Month and Insurance

Foundayo self-pay pricing starts at $149 per month for the lowest dose through Lilly’s direct-to-consumer channel. Patients with commercial insurance may pay as little as $25 per month using the manufacturer savings card, subject to eligibility. Eligible Medicare Part D patients can access Foundayo for $50 per month starting July 1, 2026. Pricing scales with dose strength, so the higher maintenance doses cost more than the starter dose. Coverage varies widely by plan, and many commercial insurers are still finalizing formulary decisions. Our team can help verify what your plan covers before you commit to a program.

Orforglipron Weight Loss and Phase 3 Results

In the ATTAIN-1 trial, adults with obesity taking orforglipron lost meaningful body weight over 72 weeks compared to placebo. Earlier phase 3 diabetes trials showed A1C reductions of up to 2.1% and clinically significant weight loss even in people without diabetes. Head-to-head data suggests orforglipron performs comparably to oral semaglutide (Rybelsus) on both A1C and weight endpoints in type 2 diabetes patients, with the added benefit of no food or water timing restrictions. Individual results vary, and weight loss depends on consistent use alongside a reduced-calorie diet and increased physical activity.

Orforglipron Dosage and Dosing Schedule

Orforglipron is taken once daily as a tablet, at any time of day, with or without food. Treatment starts at the lowest dose and is titrated up gradually over several weeks to reduce gastrointestinal side effects. This step-up schedule is standard for all GLP-1 medications and helps your body adjust. Your prescribing physician determines the maintenance dose based on how you tolerate the medication and how you’re responding to it. Skipping doses or stopping suddenly can affect appetite regulation, so consistency matters.

Orforglipron Side Effects

The most common side effects reported in trials were nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, and hair loss. Most GI symptoms are dose-related and tend to fade as your body adjusts. Foundayo carries a boxed warning for potential thyroid C-cell tumors, including medullary thyroid carcinoma. It should not be used in anyone with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2. Rare but serious risks include pancreatitis, gallbladder problems, and severe hypoglycemia when combined with insulin or sulfonylureas.

Orforglipron vs Tirzepatide, Zepbound, Semaglutide and Wegovy

Here’s how orforglipron stacks up against the current GLP-1 field:

• Orforglipron vs Tirzepatide (Mounjaro): Tirzepatide is a weekly injectable that targets both GLP-1 and GIP receptors, and it typically produces higher average weight loss in head-to-head-style comparisons. Orforglipron wins on convenience.
  
  
• Orforglipron vs Zepbound: Zepbound is tirzepatide branded for weight loss and remains a stronger option for larger total weight reduction. Orforglipron is the better fit for patients who cannot or will not inject.
  
  
• Orforglipron vs Semaglutide (Ozempic, Rybelsus, Wegovy pill): Both are oral options now, but Rybelsus requires an empty stomach and 30 minutes before food or water. Orforglipron has no such restriction. Weight loss magnitude appears similar in early comparisons.
  
  
• Orforglipron vs Retatrutide: Retatrutide is still investigational and shows very high weight loss potential in trials but is not yet FDA-approved.

When Will Orforglipron Be Available and Where to Buy It

Foundayo is available now through licensed U.S. pharmacies with a prescription from a qualified provider. Eli Lilly offers a direct-to-consumer self-pay option through its LillyDirect platform. It is not sold over the counter, and any website offering orforglipron “for sale” without a prescription is not a legitimate source. Always fill through a verified pharmacy.

Where Orforglipron Fits at BodEvolve Bariatric

At BodEvolve, we treat GLP-1 medications like Foundayo as one tool in a broader plan, not a standalone answer. Our medical weight management program combines FDA-approved medications with nutrition coaching, lab work, and physician monitoring so results actually last. For patients who need more than medication can offer, we perform gastric sleeve, gastric bypass, and duodenal switch procedures across our Arlington, Dallas, Richardson and Texarkana locations. Whether orforglipron is right for you depends on your BMI, comorbidities, insurance, and long-term goals, and that is a conversation worth having with a board-certified team. Learn more about our full range of bariatric procedures or schedule a consultation to see where you actually stand.